1. Clinical & Scientific Overview
L-Ornithine L-Aspartate (LOLA) (TIP-MED-000301, Reference Code [5.21]-C31) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [5.21] (Rifaximin & L-Ornithine L-Aspartate (LOLA)). Representative Indian Market Examples (Edition 2.7 Ch 05 [5.21], p. 70): Rifaximin: Rcifax (Lupin), Rifagut (Sun), Torfix (Torrent). LOLA: Hepa-Merz (Win-Medicare), Hepa-Sachet — Strengths & Dosage Forms: Rifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule
Rifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule
3. Mechanism of Action & Pharmacodynamics
Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Schedule H) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Schedule H) for Overt & covert Hepatic Encephalopathy (secondary prophylaxis alongside Lactulose in decompensated cirrhosis); Rifaximin 400/550 mg TDS x 14d is also used for diarrhoea-predominant IBS (IBS-D) and non-invasive traveller's diarrhoea.
4. Therapeutic Indications & Evidence-Supported Uses
- Overt & covert Hepatic Encephalopathy (secondary prophylaxis alongside Lactulose in decompensated cirrhosis)
- Rifaximin 400/550 mg TDS x 14d is also used for diarrhoea-predominant IBS (IBS-D) and non-invasive traveller's diarrhoea
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Hepatic Encephalopathy: Rifaximin 550 mg PO BD (or 400 mg TDS) continuously alongside Lactulose (titrated to 2–3 soft stools/day) + LOLA 1–2 sachets (3–6 g) dissolved in water PO BD–TDS. Traveller's Diarrhoea: Rifaximin 200 mg TDS x 3d
Administration & Meal Timing: Rifaximin may be taken with or without food; dissolve LOLA granules in a glass of water/juice and drink with or after meals | Morning & Evening (BD for Rifaximin 550 mg) or TDS (400 mg / LOLA)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [5.21].
Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy
Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy
Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy
7. Contraindications, Precautions & High-Risk Warnings
- Rifaximin: Contraindicated in invasive febrile/bloody dysentery (<0.4% systemic absorption, so ineffective for systemic infections!). LOLA: Contraindicated in severe renal failure (Serum Creatinine >3.0 mg/dL)!
Key Clinical Precautions: Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy
8. Adverse Effects Profile
- Flatulence, mild abdominal pain, headache, peripheral oedema; LOLA IV >5 g/h causes nausea/vomiting
- In Child–Pugh C cirrhosis, systemic exposure of Rifaximin increases 10–20-fold (caution with P-gp inhibitors); rare C. difficile colitis
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Cyclosporine (potent P-gp/OATP inhibitor) increases systemic Rifaximin AUC 80–120-fold; monitor INR if on Warfarin
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [5.21].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Rifaximin acts locally inside the intestine to stop gut bacteria from producing ammonia gas that clouds the brain; continue taking alongside Lactulose every day even when feeling clear-headed
- Meal & Clock Timing Instruction: Rifaximin may be taken with or without food; dissolve LOLA granules in a glass of water/juice and drink with or after meals (Morning & Evening (BD for Rifaximin 550 mg) or TDS (400 mg / LOLA))
- Missed Dose Protocol: Take as soon as remembered; never stop Rifaximin or Lactulose abruptly in cirrhosis (precipitates hepatic coma!)
- Geriatric Dispensing Pearl: Screen older cirrhotic patients for constipation, dehydration, diuretic hypokalaemia, or sedatives (BZDs) as triggers of encephalopathy
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Rifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.5] Famotidine — Histamine H2-Receptor Antagonist (H2 Blocker)
- [5.6] Domperidone — Peripheral Dopamine D2-Receptor Antagonist; Gastroprokinetic & An
- [5.7] Ondansetron — Selective Serotonin 5-HT3 Receptor Antagonist; Central & Peripher
- [5.8] Lactulose — Synthetic Non-Absorbable Disaccharide (Galactose-Fructose); Osmot
